Double-blind Controlled Trial of a Micronized Preparation of Flumedroxone (Demigran) in Prophylaxis of Migraine

Publisher Website
Google Scholar
Abstract
A double-blind cross-over trial of a micronized preparation of flumedroxone, an oral progestogen derivative, and a placebo was undertaken to determine whether this drug had prophylactic value in migraine. No benefit was found in males, or in females with no history of menstrual exacerbation of migraine. In women whose migraine was worse around the time of menstruation flumedroxone resulted in statistically fewer headaches of less severity. With the dose used in this trial (micronized flumedroxone 10 mg. t.d.s.) side-effects were frequent, the commonest being polymenorrhagia, which occurred in half the women of reproductive age.